Ontology type: schema:MonetaryGrant
2008-2011
FUNDING AMOUNT2967008 EUR
ABSTRACTANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology. More... »
URL
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2210",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"type": "DefinedTerm"
}
],
"amount": {
"currency": "EUR",
"type": "MonetaryAmount",
"value": "2967008"
},
"description": "ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform \u2013 carbon nanotubes \u2013 and apply them to a clinically established therapeutic modality \u2013 targeted antibody therapy \u2013 for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents \u2013 antibodies \u2013 with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.",
"endDate": "2011-08-31T00:00:00Z",
"funder": {
"id": "https://www.grid.ac/institutes/grid.270680.b",
"type": "Organization"
},
"id": "sg:grant.3773714",
"identifier": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"3773714"
]
},
{
"name": "cordis_id",
"type": "PropertyValue",
"value": [
"86759"
]
}
],
"inLanguage": [
"en"
],
"keywords": [
"sophisticated nanotechnologies",
"antibodies",
"new paradigm",
"advanced biotech",
"proposal",
"drug delivery",
"oncology",
"therapeutic modalities",
"field",
"tumor cell cytoplasm",
"ANTICARB",
"industry-academia multidisciplinary",
"carbon",
"clinical oncology settings",
"carbon nanotubes",
"anti-cancer agents",
"cancer",
"antibody-nanotube conjugates",
"antibody therapy",
"multidisciplinary approach",
"platform",
"therapeutic potency",
"engineering",
"validation",
"molecular biology",
"monoclonal antibodies",
"toxicology",
"advantages",
"creation",
"expertise",
"technology",
"chemistry",
"pharmacology",
"ability",
"oncology therapeutics",
"OBJECTIVE",
"specific intracellular targets",
"ANTICARB attempts",
"advanced nanomaterials",
"nanotube technology",
"cancer therapeutics",
"safe development",
"novel nanotechnology platforms",
"integrated team",
"novel nanotechnology",
"hybrid nanotechnology",
"swift translation",
"CARBon nanobues",
"way"
],
"name": "Monoclonal ANTIbody-targeted CARBon nanobues against cancer",
"recipient": [
{
"id": "https://www.grid.ac/institutes/grid.5133.4",
"type": "Organization"
}
],
"sameAs": [
"https://app.dimensions.ai/details/grant/grant.3773714"
],
"sdDataset": "grants",
"sdDatePublished": "2019-03-07T11:22",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/cordis_projects_2.xml.gz",
"startDate": "2008-03-01T00:00:00Z",
"type": "MonetaryGrant",
"url": "http://cordis.europa.eu/project/rcn/86759_en.html"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.3773714'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.3773714'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.3773714'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.3773714'
This table displays all metadata directly associated to this object as RDF triples.
83 TRIPLES
19 PREDICATES
69 URIs
62 LITERALS
4 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:grant.3773714 | schema:about | anzsrc-for:2210 |
2 | ″ | schema:amount | N66f302cb6aa04e5abda309ff46e8e70a |
3 | ″ | schema:description | ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology. |
4 | ″ | schema:endDate | 2011-08-31T00:00:00Z |
5 | ″ | schema:funder | https://www.grid.ac/institutes/grid.270680.b |
6 | ″ | schema:identifier | Naa8082d5c393431bb0a596385e1fe65f |
7 | ″ | ″ | Nacff56838c084d87becc07884946fdf7 |
8 | ″ | schema:inLanguage | en |
9 | ″ | schema:keywords | ANTICARB |
10 | ″ | ″ | ANTICARB attempts |
11 | ″ | ″ | CARBon nanobues |
12 | ″ | ″ | OBJECTIVE |
13 | ″ | ″ | ability |
14 | ″ | ″ | advanced biotech |
15 | ″ | ″ | advanced nanomaterials |
16 | ″ | ″ | advantages |
17 | ″ | ″ | anti-cancer agents |
18 | ″ | ″ | antibodies |
19 | ″ | ″ | antibody therapy |
20 | ″ | ″ | antibody-nanotube conjugates |
21 | ″ | ″ | cancer |
22 | ″ | ″ | cancer therapeutics |
23 | ″ | ″ | carbon |
24 | ″ | ″ | carbon nanotubes |
25 | ″ | ″ | chemistry |
26 | ″ | ″ | clinical oncology settings |
27 | ″ | ″ | creation |
28 | ″ | ″ | drug delivery |
29 | ″ | ″ | engineering |
30 | ″ | ″ | expertise |
31 | ″ | ″ | field |
32 | ″ | ″ | hybrid nanotechnology |
33 | ″ | ″ | industry-academia multidisciplinary |
34 | ″ | ″ | integrated team |
35 | ″ | ″ | molecular biology |
36 | ″ | ″ | monoclonal antibodies |
37 | ″ | ″ | multidisciplinary approach |
38 | ″ | ″ | nanotube technology |
39 | ″ | ″ | new paradigm |
40 | ″ | ″ | novel nanotechnology |
41 | ″ | ″ | novel nanotechnology platforms |
42 | ″ | ″ | oncology |
43 | ″ | ″ | oncology therapeutics |
44 | ″ | ″ | pharmacology |
45 | ″ | ″ | platform |
46 | ″ | ″ | proposal |
47 | ″ | ″ | safe development |
48 | ″ | ″ | sophisticated nanotechnologies |
49 | ″ | ″ | specific intracellular targets |
50 | ″ | ″ | swift translation |
51 | ″ | ″ | technology |
52 | ″ | ″ | therapeutic modalities |
53 | ″ | ″ | therapeutic potency |
54 | ″ | ″ | toxicology |
55 | ″ | ″ | tumor cell cytoplasm |
56 | ″ | ″ | validation |
57 | ″ | ″ | way |
58 | ″ | schema:name | Monoclonal ANTIbody-targeted CARBon nanobues against cancer |
59 | ″ | schema:recipient | https://www.grid.ac/institutes/grid.5133.4 |
60 | ″ | schema:sameAs | https://app.dimensions.ai/details/grant/grant.3773714 |
61 | ″ | schema:sdDatePublished | 2019-03-07T11:22 |
62 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
63 | ″ | schema:sdPublisher | N68fdaaedd634446a9627c78eaeab7f81 |
64 | ″ | schema:startDate | 2008-03-01T00:00:00Z |
65 | ″ | schema:url | http://cordis.europa.eu/project/rcn/86759_en.html |
66 | ″ | sgo:license | sg:explorer/license/ |
67 | ″ | sgo:sdDataset | grants |
68 | ″ | rdf:type | schema:MonetaryGrant |
69 | N66f302cb6aa04e5abda309ff46e8e70a | schema:currency | EUR |
70 | ″ | schema:value | 2967008 |
71 | ″ | rdf:type | schema:MonetaryAmount |
72 | N68fdaaedd634446a9627c78eaeab7f81 | schema:name | Springer Nature - SN SciGraph project |
73 | ″ | rdf:type | schema:Organization |
74 | Naa8082d5c393431bb0a596385e1fe65f | schema:name | cordis_id |
75 | ″ | schema:value | 86759 |
76 | ″ | rdf:type | schema:PropertyValue |
77 | Nacff56838c084d87becc07884946fdf7 | schema:name | dimensions_id |
78 | ″ | schema:value | 3773714 |
79 | ″ | rdf:type | schema:PropertyValue |
80 | anzsrc-for:2210 | schema:inDefinedTermSet | anzsrc-for: |
81 | ″ | rdf:type | schema:DefinedTerm |
82 | https://www.grid.ac/institutes/grid.270680.b | ″ | schema:Organization |
83 | https://www.grid.ac/institutes/grid.5133.4 | ″ | schema:Organization |